Social media gurus flee to agency side

Share this article:
Two of the drug industry's top social media experts, Shwen Gwee and Marc Monseau, are changing jobs.
Shwen Gwee is leaving Vertex to co-lead Edelman's digital health practice.
Gwee, one of the drug industry's top digital and social media gurus, will work out of Edelman's New York office and report to Bruce Hayes, general manager of Edelman's New York healthcare practice, where he'll join former AstraZeneca marketer Gigi Peterkin. Gwee was digital strategy and social media lead at Vertex for several years and also co-founded the Social Health Unconference and the SocialPharmer Network. He's also a member of MM&M's editorial advisory board.
Gwee said on his Med2.0 blog: “While I was able to roll out some cool and interesting digital initiatives during my time at Vertex, my new role at Edelman will allow me to serve the industry in a greater capacity and spread my wings more broadly by challenging me to think across multiple audiences, diseases, and brands/clients.”
At Vertex, Gwee built an industry-leading corporate social media infrastructure and plotted a consumer media strategy, most recently launching a corporate Twitter account and a digital hepatitis C disease education company that features a YouTube Channel and a Slideshare Page.
Monseau, who has been with J&J for 14 years, including three as director of corporate communication and social media, is leaving the company to open up his own firm, MDM Communications, which “will provide social and digital communication support focusing on healthcare and related industries to help companies become more involved in the social web,” he told MM&M.
Share this article:

Email Newsletters

More in Features

Headliner: Proteus CEO takes an original path

Headliner: Proteus CEO takes an original path

Andrew Thompson, CEO, Proteus Digital Health

Leadership Exchange: How Do We Get Beyond the Pill?

Leadership Exchange: How Do We Get Beyond the ...

As its focus moves from manufacturing to service, pharma needs to partner with healthcare neophytes as well as established players. James Chase asks six experts to assess the risks and ...

FDA and off-label uses: a balancing act

FDA and off-label uses: a balancing act

FDA's current re-examination of its off-label promotion policies in light of the First Amendment is a delicate balancing act between its rock-solid traditional enforcement posture and a diverse new electronic ...